Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04745949
Title PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy (PACIFIC)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center

primary mediastinal B-cell lymphoma


Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Nivolumab + Prednisone + Rituximab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.